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INTRODUCTION
Hemodialysis is the most common renal replacement ther-
apy for patients with end-stage renal disease (ESRD).1 Hemo-
dialysis patients may suffer from psychological distress and 
reduced quality of life, which is related to chronic physical 
health problems.2
ESRD patients may also have several medical comorbidities 
that have a significant impact on their quality of life.3 Also, 
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emotional distress, including anxiety and depression, may con-
tribute to deterioration in quality of life of this patient group.2 
C-reactive protein (CRP) level has been reported to be associ-
ated with chronic inflammatory status, which has been asso-
ciated with depression.4
Genetic polymorphism in serotonin receptor, neurotrophic 
factor, and glucocorticoid receptor function is known to also 
be associated with anxiety and depression, which may under-
mine the quality of life of ESRD patients. Dysfunction of the 
serotonergic system of the central nervous system is involved 
in the pathogenesis of depressive illness. Patients with depres-
sion have fewer serotonin transporters and serotonin 1A re-
ceptors (5-HT1A receptors).5 A common promoter polymor-
phism (C-1019G; rs6295) of 5-HT1A receptors gene (HTR1A) 
has been known to be associated with psychiatric illness such 
as major depression and suicide,6 and anxiety-depression 
prone personality traits.7 Brain-derived neurotrophic factor 
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gene (BDNF) polymorphism in human (rs6265) is also known 
to be associated with major depression8 and antidepressant 
treatment outcome.9,10 Genetic polymorphism in FK506 bind-
ing protein 5 (FKBP5) has a stress-sensitive effect on its inter-
actions with glucocorticoid receptor proteins, and such poly-
morphisms are known to be associated with anxiety and 
depression in various clinical populations.11,12 However, the 
relationship between these genetic polymorphisms associated 
with depression and anxiety, and the quality of life of ESRD 
patients has not yet been sufficiently investigated.13 The aim 
of this study was to investigate the relationship between genet-
ic polymorphisms and other clinical characteristics, and the 
health-related variation in quality of life of Korean hemodial-
ysis patients. We hypothesized that SNPs associated with vul-
nerability to emotional distress may have a significant rela-
tionship with decreased quality of life in the ESRD patients.
METHODS
Subjects
A total of 245 clinically stable patients (154 male/87 female) 
from 6 hemodialysis centers participated in this study with 
informed consent. The average age of the participants was 
54.66 (±12.65) years, and the mean duration of education was 
12.05 (±3.89) years. On average, participants had received 
hemodialysis for 86.51 (±74.28) months, and had 1.41 (±0.91) 
comorbid diseases. Serum CRP level, blood urea nitrogen, 
creatinine, and high-density lipoprotein (HDL) cholesterol 
levels were assessed and KT/V1 was calculated from pre- and 
post-dialysis blood specimens to evaluate the hemodialysis 
adequacy.14
Health-related quality of life and emotional distress 
assessment
A 36-item Short-Form Health Survey (SF-36) was used to 
assess the health-related quality of life (QoL) of each partici-
pant.15 The 36 items of this short questionnaire measure eight 
variables: physical functioning (10 items), social functioning 
(two items), role limitation due to physical problems (four 
items), role limitation due to emotional problems (three items), 
mental health (five items), energy and vitality (four items), 
pain (two items), and general perception of health (five items). 
There is a single item on further changes in respondents’ health 
over the past year.15 The eight variables are hypothesized to 
form two distinct higher-ordered clusters due to the physical 
and mental health variance that they have in common.16 The 
score of these two clusters were analyzed as variances of men-
tal and physical QoL in this study. For each variable item scores 
were coded, summed, and transformed on to a scale from 0 
(worst possible health state measured by the questionnaire) 
to 100 (best possible health state). The validity of the Korean-
version of SF-36 was tested in several studies.17,18 In addition, 
psychological distress, such as depression and anxiety, were 
assessed using the Hospital Anxiety and Depression Scale 
(HADS).19 This scale was divided into an anxiety subscale 
(HADS-A) and a depression subscale (HADS-D), both of 
which contained seven questionnaire items.20 All items are 
scored on a 4 point scale from 0 to 3. The HADS was previ-
ously proven to measure the anxiety and depression validity 
in Korean population.21
Genetic polymorphism
Genetic polymorphism of HTR1A, BDNF, and glucocorti-
coid receptor (FKBP5) were assessed. For genotyping, genom-
ic DNA was isolated from EDTA-pretreated venous blood 
samples. The DNA fragments of interest were amplified by us-
ing a polymerase chain reaction (PCR). Three SNPs, rs6295 in 
HTR1A,7 rs6265 in BDNF,22 rs9296158 in FKBP5,11 were se-
lected from among HTR1A, BDNF, FKBP5 variants identified 
in dbSNP (http://www.ncbi.nlm.nih.gov/SNP) as having func-
tional significance. These three SNPs were previously investi-
gated with respect to vulnerability to emotional distress and 
reduction of QoL level. The genotyping was screened with a 
single-base primer extension assay using an ABI PRISM® 
SNaPshotTM Multiplex Kit (Thermo Fisher Scientific, Waltham, 
MA, USA) according to the manufacturer’s instructions. Anal-
yses were performed using Genemapper Software version 4.0 
(Thermo Fisher Scientific).
Statistical analyses
Statistical analyses were done using the SPSS version 20 
(IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: 
IBM Corp.). The testing for Hardy-Weinberg equilibrium was 
conducted using the chi-square test. Independent sample t-
tests were conducted to compare physical and mental QoL 
level depending on HTR1A, BDNF, FKBP5 genetic polymor-
phisms. Correlation analyses were also performed to observe 
relationships between QoL levels and clinical characteristics in 
hemodialysispatients. Finally, multiple linear regression analy-
ses were conducted to find significant factors which contribute 
physical and mental QoL in hemodialysis patients. All the tests 
were two-sided and probability value (p) less than 0.05 was 
considered statistically significant.
Ethics statement
The study protocol was approved by the Institutional Re-
view Board of Gangnam Severance Hospital, Yonsei University 
College of Medicine (IRB No. 3-2012-0176). Informed con-
sent was confirmed by the IRB.
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RESULTS
For the HTR1A polymorphism, the most prevalent geno-
type was GG (n=149, 60.8%), followed by GC (n=80, 32.7%), 
and CC (n=16, 6.5%). For the BDNF Val66Met, the most 
prevalent genotype was GA (n=117, 47.8%), followed by GG 
(n=82, 33.5%), and CC (n=46, 18.8%). In addition, for the 
FKBP5, CC (n=115, 46.9%) genotype was the most common, 
followed by CT (n=106, 43.3%), and TT (n=24, 9.8%). The 
genotype distribution of the HTR1A, BDNF and FKBP5 poly-
morphism was in accordance with the Hardy-Weinberg equi-
librium (χ2=1.34, p=0.246, χ2=0.139, p=0.709, and χ2=0.0035, 
p=0.953, respectively).
The results of a comparison of the physical and mental QoL 
levels depending on genetic polymorphism were summarized 
in Figure 1. Individuals with the CC genotype of serotonin 1A 
receptor promoter (rs6295) had a significantly higher QoL lev-
elthan those with the GG/GC genotypes (physical QoL 
243.2±67.0 vs. 199.3±78.3, t=-2.12, df=229, p=0.035; mental 
QoL 259.0±58.9 vs. 208.0±69.1, t=-2.871, df=231, p=0.004).
However, there was no significant difference between the gen-
otypes of BDNF (GG vs. GA/AA: physical QoL 203.1±77.8 vs. 
200.4±79.6, t=0.235, df=229, p=0.81; mental QoL 211.5±68.9 
vs. 211.5±71.3, t=0.001, df=231, p=0.99) or glucocorticoid re-
ceptor polymorphism (CC/CT vs. TT: physical QoL 204.4±78.1 
vs. 181.7±77.6, t=1.321, df=229, p=0.188; mental QoL 212.8± 
Figure 1. Comparison of physical and mental quality of life in hemodialysis patients according to genetic polymorphisms of serotonin 1A re-
ceptor (5HTR1A), brain-derived neurotrophic factor (BDNF), and glucocorticoid receptor (FKBP5). *p<0.05.
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Table 1. Comparison of clinical characteristics of the hemodialysis patients depending on their genotypes
HTR1A (rs6295) BDNF (rs6265) FKBP5 (rs9296158)
GG/GC
(N=229)
CC
(N=16)
Sig.
GA/AA
(N=163)
GG
(N=82)
Sig.
CC/CT
(N=221)
TT
(N=24)
Sig.
Age (year) 54.6
(12.6)
55.5
(12.3)
0.76 53.7
(13.1)
56.4
(11.4)
0.13 54.8
(12.4)
52.9
(14.3)
0.47
Education (year) 12.0
(3.8)
12.5
(4.2)
0.58 11.9
(3.8)
12.2
(3.9)
0.56 12.1
(3.8)
10.6
(4.1)
0.067
Anxiety 5.6
(3.8)
5.4
(4.3)
0.84 5.8
(3.9)
5.2
(3.7)
0.23 5.4*
(3.7)
7.1*
(4.5)
0.044
Depression 7.5
(4.0)
6.3
(4.0)
0.22 7.4
(3.9)
7.5
(4.1)
0.91 7.3
(3.9)
8.6
(4.9)
0.13
CRP 0.8
(2.2)
0.2
(0.2)
0.40 0.67
(1.6)
0.94
(2.8)
0.42 0.8
(2.2)
0.3
(0.3)
0.31
KT/V1 1.55
(0.2)
1.53
(0.3)
0.80 1.5
(0.2)
1.5
(0.2)
0.82 1.5
(0.2)
1.5
(0.2)
0.99
Dialysis months 87.6
(74.6)
72.0
(69.6)
0.41 89.0
(78.6)
81.6
(65.1)
0.47 87.0
(74.7)
81.8
(71.5)
0.74
No. of medical comorbidity 1.4
(0.9)
1.3
(0.8)
0.88 1.3
(0.9)
1.4
(0.9)
0.33 1.4
(0.9)
1.4
(0.8)
0.96
Independent sample t-tests were conducted. Data are presented as means (SD). *p<0.05. CRP: C-reactive protein, KT/V1: an index for dialy-
sis treatment adequacy, HTR1A: serotonin 1A receptor polymorphism, BDNF: brain derived neurotrophic factor polymorphism, FKBP5: 
glucocorticoid receptor polymorphism
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69.8 vs. 200.1±68.3, t=0.829, df=231, p=0.40). The FKBP5 TT 
genotype group showed a slightly higher anxiety score com-
pared to the CC/CT genotype group, but this result was clinical-
ly not significant (Table 1).
As shown in Table 2, physicalQoL level was found to be sig-
nificantly correlated with age (r=-0.213, p=0.001), anxiety (r= 
-0.466, p<0.001), depression (r=-0.582, p<0.001), total hemo-
dialysis duration (r=-0.231, p=0.001), the number of comorbid 
medical illnesses (r=-0.191, p=0.004), blood urea nitrogen 
(r=0.138, p=0.038), CRP (r=-0.170, p=0.028), and high-densi-
ty lipoprotein (HDL) cholesterol levels (r=0.169, p=0.011). 
MentalQoL was significantly correlated with anxiety (r=-0.619, 
p<0.001), depression (r=-0.648, p<0.001), total hemodialysis 
duration (r=-0.149, p=0.027), the number of comorbid medical 
illnesses (r=-0.17, p=0.009), serum CRP (r=-0.175, p=0.023), 
and HDL cholesterol levels (r=0.169, p=0.011).
Anxiety and depression levels were significantly correlated 
with all variables of health related QoL assessed using SF-36. 
The number of comorbid medical illnesses was significantly 
inversely correlated with almost variables of QoL including 
physical function (r=-0.162, p=0.012), bodily pain (r=-0.162, 
p=0.012), general health (r=-0.237, p<0.001), social function-
ing (r=-0.159, p=0.014), emotional role limitation (r=-0.144, 
p=0.025), and mental health (r=-0.139, p=0.031). Total dialysis 
duration was also inversely correlated with physical role limi-
tation (r=-0.213, p=0.001), bodily pain (r=-0.188, p=0.013), 
social functioning (r=-0.190, p=0.004). CRP level was inverse-
ly correlated with bodily pain (r=-0.188, p=0.013), general 
health (r=-0.167, p=0.028), mental health (r=-0.152, p=0.046). 
HDL cholesterol level showed a positive correlation with phys-
ical (r=0.165, p=0.011)and emotional role limitation (r=0.151, 
p=0.020), bodily pain (r=0.194, p=0.003), and social function-
ing (r=0.183, p=0.005).
As shown in Table 3, physical QoL level was significantly as-
sociated with age (B=-1.615, p=0.003), depression (B=-8.568, 
p<0.001), and medical comorbidity (B=-15.602, p=0.045). 
Mental QoL level was associated with age (B=-0.962, p=0.023), 
anxiety (B=-5.606, p=0.001), and depression (B=-5.437, 
p=0.001). Furthermore, the CC genotype of serotonin 1A re-
ceptor was positively correlated with both physical (B=55.974, 
Table 2. Bivariate correlation analyses between health-related quality of life variables and clinical characteristicsin thehemodialysis patients
Age Edu.
Comor-
bidity
Dialys. 
dur.
Anx. Dep. CRP BUN Cr. T chol. HDL-C KT/V1
QoL_phy. r -0.213* 0.109 -0.191* -0.231* -0.466* -0.582* -0.170* 0.138* 0.117 0.035 0.192* 0.055
p 0.001* 0.100 0.004* 0.001* <0.001* <0.001* 0.028* 0.038* 0.078 0.59 0.004* 0.45
QoL_men. r -0.115 0.088 -0.170* -0.149* -0.619* -0.648* -0.175* 0.067 0.074 0.056 0.169* 0.025
p 0.084 0.18 0.009* 0.027* <0.001* <0.001* 0.023* 0.31 0.26 0.40 0.011* 0.72
PF r -0.315* 0.122 -0.162* -0.081 -0.232* -0.387* -0.078 0.177* 0.244* -0.006 0.092 -0.006
p <0.001* 0.061 0.012* 0.22 <0.001* <0.001* 0.30 0.006* <0.001* 0.92 0.15 0.93
RP r -0.196* 0.100 -0.062 -0.213* -0.334* -0.369* -0.083 0.098 0.060 0.012 0.165* 0.039
p 0.003* 0.12 0.34 0.001* <0.001* <0.001* 0.27 0.13 0.35 0.85 0.011* 0.58
BP r -0.074 0.042 -0.162* -0.183* -0.479* -0.531* -0.188* 0.014 -0.009 0.072 0.194* 0.085
p 0.25 0.52 0.012* 0.006* <0.001* <0.001* 0.013* 0.82 0.88 0.26 0.003* 0.22
GH r -0.015 -0.028 -0.237* -0.125 -0.417* -0.538* -0.167* 0.073 0.012 0.074 0.106 0.064
p 0.81 0.67 <0.001* 0.063 <0.001* <0.001* 0.028* 0.26 0.85 0.25 0.10 0.37
VT r -0.147* 0.146* -0.084 -0.104 -0.382* -0.525* -0.124 0.099 0.088 0.061 0.091 -0.005
p 0.025* 0.025* 0.19 0.11 <0.001* <0.001* 0.10 0.13 0.17 0.34 0.16 0.94
SF r -0.072 -0.001 -0.159* -0.190* -0.522* -0.530* -0.132 0.045 0.064 0.040 0.183* 0.025
p 0.27 0.98 0.014* 0.004* <0.001* <0.001* 0.083 0.49 0.32 0.53 0.005* 0.72
RE r -0.225* 0.105 -0.144* -0.092 -0.446* -0.473* -0.123 0.130* 0.132* 0.010 0.151* 0.095
p 0.001* 0.10 0.025* 0.16 <0.001* <0.001* 0.10 0.045* 0.041* 0.87 0.020* 0.17
MH r 0.034 0.086 -0.139* -0.081 -0.631* -0.595* -0.152* -0.025 -0.038 0.087 0.114 0.017
p 0.60 0.19 0.031* 0.22 <0.001* <0.001* 0.046* 0.70 0.55 0.18 0.081 0.81
*Pearson Correlation analyses were performed. Statistically significant results. Edu: education level, Dialys. dur.: dialysis duration, Anx.: anxi-
ety, Dep.: depression, CRP: C-reactive protein, BUN: blood urea nitrogen, Cr.: creatinine, T chol.: total cholesterol, HDL-C: high-density lipo-
protein cholesterol, KT/V1: an index for dialysis treatment adequacy, QoL_phy.: global physical quality of life, QoL_men.: global mental 
quality of life, PF: physical functioning, RP: role limitation-physical, BP: bodily pain, GH: general health, VT: vitality, SF: social functioning, 
RE: role limitation-emotional, MH: mental health
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p=0.038) and mental (B=51.145, p=0.010) QoL level. No sig-
nificant association was found between the other genetic poly-
morphisms, clinical characteristics, and the QoL level in ESRD 
patients.
DISCUSSION
In this study, a polymorphism in HTR1A was found to be 
significantly associated with mental and physical QOL in 
ESRD patients. Patients with the CC genotype of the SNP 
(rs6295) in the promoter region of HTR1A gene had a signif-
icantly higher QoL level than patients with the GG/GC geno-
types. This finding suggests that patients with the HTR1A G 
allele may suffer from a reduced QoL. The G allele has mostly 
been associated with an increased vulnerability to psychologi-
cal distress, such as depression, anxiety and chronic stress,23-25 
even thoughprevious studies that have investigated the role 
of HTR1A polymorphisms in psychological distress have re-
ported mixed results in healthy volunteers and clinical patient 
samples. In support of these findings, several studies have re-
ported that carriers of the G allele respond less well to antide-
pressant treatment.26,27 The G allele also appears to be associ-
ated with higher neuroticism scores on the NEO personality 
inventory (NEO-PI-R), mainly due to associations with the 
anxiety and depression facets of neuroticism.7 In addition, 
several recent studies reported the emotional and behavioral 
characteristics of individuals with G alleles. One study dem-
onstrated that the HTR1A rs6295 G allele is correlated with 
enhanced threat-related information processing, which con-
fers vulnerability to stress-related psychiatric disorders.28 Fur-
thermore, an HTR1A polymorphism was reported to be as-
sociated with attenuated serotonergic tone and to affect pain 
perception.29 Therefore, the HTR1A rs6295 G allele may have 
a negative impact on the capacity of ESRD patients to cope 
with chronic stress and pain, and ultimately lower their QoL.
In contrast to the result from HTR1A, polymorphism in 
BDNF and FKBP5 did not show any significant associations in 
this study. Previousgenetic studydid not find significant effects 
of serotonin transporter or BDNF Val66Met genetic polymor-
phism on major depression among the hemodialysis patient.13 
Our work has contributed to find a stress-related genetic poly-
morphism in ESRD patients by revealing the unique effect of 
polymorphism in serotonin 1A receptor on their quality of life. 
Considering previous research, HTR1A has been reported to 
be associated with many quality-of-life domains, such as dis-
ease-related pain, pain perception,29,30 depression,31-33 and 
chronic fatigue,34 while the genes BDNF and FKBP5 have a 
comparatively limited effect on QoL.35 This may be one expla-
nation for our result, but the difference between genetic poly-
morphisms in their effect on QoL requires further study.
Age, depression, medical comorbidity, and HTR1A poly-
morphism were revealed to have significant associations with 
the quality of life of ESRD patientsin the final regression analy-
sis.Older age was associated with a lower QoL, and this finding 
has already been mentioned in a study of the general popula-
tion, and studies of ESRD patients.36 Age has mostly been sug-
gested as one of the main determinants of QoL that is not asso-
ciated with renal disease, nor intensified by it37 although there 
have been other inconsistent result.38 We also found that QoL 
was negatively affected by depression in hemodialysis patients. 
This result is in line with previous studies, which suggested that 
a depressed mood may lead to a less favorable perception about 
Table 3. Relationship between health-related quality of life levels and genetic polymorphisms, emotional distress, and clinical characteris-
tics in hemodialysis patients
Physical quality of life Mental quality of life
B S.E t Sig. B S.E t Sig.
Age -1.615* 0.533* -3.031* 0.003* -0.962* 0.417* -2.309* 0.023*
Anxiety -1.784 2.204 -0.809 0.42 -5.606* 1.697* -3.302* 0.001*
Depression -8.568* 1.929* -4.441* <0.001* -5.437* 1.525* -3.565* 0.001*
Medical comorbidity -15.602* 7.677* -2.032* 0.045* -8.699 5.945 -1.463 0.14
Dialys. dur. -0.125 0.075 -1.662 0.099 -0.056 0.058 -0.955 0.34
CRP -1.481 2.623 -0.565 0.57 -1.151 2.036 -0.565 0.57
KT/V-1 -10.608 23.78 -0.446 0.65 -15.813 18.165 -0.870 0.38
HTR1A_C 55.974* 26.653* 2.100* 0.038* 51.145* 19.526* 2.619* 0.010*
BDNF_G 10.924 12.903 0.847 0.39 3.914 10.007 0.391 0.69
FKBP5_T -30.804 20.428 -1.508 0.13 -1.828 16.01 -0.114 0.90
Model summary F=10.143, p<0.001, R2=0.487 F=12.133, p<0.001, R2=0.524
*multiple regression analyses were performed. Statistically significant results. Dialys. dur.: dialysis duration, CRP: C-reactive protein, KT/V1: 
an index for dialysis treatment adequacy, HTR1A_C: serotonin 1A receptor polymorphism (CC type), BDNF-G: brain derived neurotrophic 
factor polymorphism (GG type), FKBP5_T: glucocorticoid receptor polymorphism (TT type)
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their life, and thus the reporting of a lower quality of life.39,40
Other clinical factors were also correlated with QoL in ESRD 
patientsin this study. An increased level of high density lipo-
protein, which is known to be positively associated with a de-
creased risk of heart disease,41 was correlated with health re-
lated QoL Level. Previous study also reported lower health-
related QoL level in people with metabolic syndrome.42 QoL 
level was also negatively correlated with the level of CRP. This 
may be interpreted as an elevation in CRP level due to stress 
reaction4 or a reduced QoL due to a worsening of medical con-
dition.36 There were other correlations between QoL and the 
number of co-morbid illnesses, and with the duration of he-
modialysis, which have both been reported to affect the QoL 
of ESRD patients.43,44
As mentioned above, the quality of life of ESRD patients was 
influenced by many clinical characteristics. It is reasonable to 
assume that the patients’ quality of life depends upon a com-
plex interaction of multiple factors, such as disease outcome, 
personal traits, coping behavior, social support, and the quality 
of the care received.44 In this regard, if clinicians could detect 
and support the ESRD patients who are more vulnerable to 
prolonged stress exposure, it would be helpful for preventing 
progression to stress-related psychiatric illnesses.
This study has three limitations. Firstly, the small sample size, 
which reduced the statistical power, which may have been in-
sufficient to detect direct correlations between depression, anx-
iety and genetic polymorphisms. Secondly, various comorbidi-
ties of ESRD patients that could have affected psychological 
status, depending on their biological impact, were not suffi-
ciently controlled in analyzing and interpreting the data. Third-
ly, the present study only examined quantitative self-reported 
distress levels and did not classify phenotypes into clinical 
mental disorders by using a structured clinical interview with 
diagnostic and statistical manual for mental disorders. History 
of psychiatric medication use was not gathered, either. In order 
to validate our findings it would be necessary to recruit a more 
homogenous group of patients, to control for other physical 
and psychiatric illnesses.
In summary, we investigated the relationship between 
health-related QoL and clinical characteristics and genetic 
polymorphism in ESRD patients. After controlling multiple 
clinical variables, polymorphism in serotonin 1A receptor, as 
well as age and depression, was significantly associated with 
physical and mental QoL in hemodialysis patients. Functional 
activity in the serotonin receptor system may have a modulat-
ing effect on QoL in hemodialysis patients. Clinicians should 
pay more attention to the genetic traits of hemodialysis pa-
tients, as well as to their age and emotional distress, to improve 
their health-related QoL.
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